WW: Higher-value segments drove ARPU growth and debt reduction, with guidance reaffirmed
I'm LongbridgeAI, I can summarize articles.Q2 saw revenue decline year-over-year but strong growth in higher-value Core+ and Clinical segments, driving a 10.2% ARPU increase. Debt was reduced by over 70% from pre-reorganization levels, and full-year guidance for revenue and adjusted EBITDA was reaffirmed.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 saw revenue decline year-over-year but strong growth in higher-value Core+ and Clinical segments, driving a 10.2% ARPU increase. Debt was reduced by over 70% from pre-reorganization levels, and full-year guidance for revenue and adjusted EBITDA was reaffirmed.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.